Patterson Companies (PDCO)
(Delayed Data from NSDQ)
$21.08 USD
-0.85 (-3.88%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $21.10 +0.02 (0.09%) 5:10 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.08 USD
-0.85 (-3.88%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $21.10 +0.02 (0.09%) 5:10 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Zacks News
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
by Zacks Equity Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Here's Why You Should Add Glaukos (GKOS) to Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), given its better-than-expected earnings and strategic alliances.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
Merit Medical's (MMSI) New Launch to Improve Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest launch will likely aid in precisely targeting affected tissues, thereby resulting in more successful surgeries and improved patient outcomes.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
by Zacks Equity Research
Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Cardinal Health (CAH) Buys Bendcare CPO-GPO, Invests in Its MSO
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly boost its distribution opportunities and improve patient service.
LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity
by Zacks Equity Research
Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.
3 Reasons to Add QuidelOrtho (QDEL) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Here's Why You Should Buy ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Reasons to Add Patterson Companies (PDCO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Merck (MRK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Company News for Jun 30, 2022
by Zacks Equity Research
Companies in The News Are: GIS,MKC,BBBY,PDCO
Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2022 results benefit from strength in the Dental and Animal Health segments.
Patterson Cos. (PDCO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 26.79% and 1.71%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Patterson Cos. (PDCO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Patterson Cos. (PDCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.